Fate Trial Disclosure
Fate Therapeutics · Fate Therapeutics, Inc · FateTrialDisclosure@fatetherapeutics.com
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fate Trial Disclosure as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:21 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05934097 · FT596 in Combination With R-CHOP in Subjects With B-Cell LymphomaFate Therapeutics · withdrawn · Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma · study director
- Ph1NCT05395052 · FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsFate Therapeutics · terminated · Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer · study director
- Ph1NCT05182073 · FT576 in Subjects With Multiple MyelomaFate Therapeutics · completed · Multiple Myeloma, Myeloma · study director
- Ph1NCT05069935 · FT538 in Combination With Monoclonal Antibodies in Advanced Solid TumorsFate Therapeutics · terminated · Solid Tumor, Adult · study director
- Ph1NCT04629729 · FT819 in Subjects With B-cell MalignanciesFate Therapeutics · active not recruiting · Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia · study director
- Ph1NCT04614636 · FT538 in Subjects With Advanced Hematologic MalignanciesFate Therapeutics · terminated · Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma · study director
- Ph1NCT04551885 · FT516 in Combination With Monoclonal Antibodies in Advanced Solid TumorsFate Therapeutics · terminated · Solid Tumor, Adult · study director
- Ph1NCT04245722 · FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal AntibodiesFate Therapeutics · terminated · Lymphoma, B-Cell, Chronic Lymphocytic Leukemia · study director
- N/ANCT04106167 · Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyFate Therapeutics · terminated · Advanced Solid Tumor, Lymphoma, Gastric Cancer · study director
- Ph1NCT04023071 · FT516 in Subjects With Advanced Hematologic MalignanciesFate Therapeutics · terminated · Acute Myelogenous Leukemia, B-cell Lymphoma · study director
- Ph1NCT03841110 · FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFate Therapeutics · completed · Advanced Solid Tumors, Lymphoma, Gastric Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in acute myeloid leukemia.